BridgeBio Pharma, Inc. (BBIO) vs ICON Public Limited Company (ICLR)
A side-by-side comparison of BridgeBio Pharma, Inc. and ICON Public Limited Company across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BBIO
BridgeBio Pharma, Inc.
$66.14HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
ICLR
ICON Public Limited Company
$168.33HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — BBIO vs ICLR
growth of $100 · dividends reinvested · last 7yBBIO +140.1% (+13.3%/yr)ICLR +12.2% (+1.7%/yr)BBIO compounded faster over this window
BBIO ICLR
BBIO vs ICLR: by the numbers
- •BBIO is the larger company ($12.95B vs $12.89B market cap).
- •ICLR is profitable (3.99% net margin) while BBIO runs a net loss (-97.64%).
- •BBIO grew revenue faster over the past five years (62.61% vs 20.93% CAGR).
Metrics side by side
Valuation
| Metric | BBIO | ICLR |
|---|---|---|
| P/E ratio | N/A | 39.51 |
| Forward P/E | N/A | 15.90 |
| P/S ratio | 18.17 | 1.56 |
| P/B ratio | N/A | 1.37 |
| EV / EBITDA | N/A | 10.94 |
| FCF yield | N/A | 10.44% |
Profitability
| Metric | BBIO | ICLR |
|---|---|---|
| Gross margin | 93.35% | 21.85% |
| Operating margin | -113.35% | 10.15% |
| Net margin | -97.64% | 3.99% |
| ROE | N/A | 3.51% |
| ROIC | -62.14% | 4.80% |
Growth (annualized)
| Metric | BBIO | ICLR |
|---|---|---|
| Revenue CAGR (5Y) | 62.61% | 20.93% |
| EPS CAGR (5Y) | N/A | -14.23% |
| FCF CAGR (5Y) | N/A | 22.10% |
| Total return CAGR (5Y) | 7.38% | -8.50% |
Frequently asked
- Which has grown faster, BBIO or ICLR?
- Over the past five years, BBIO grew revenue faster — BBIO at a 62.61% CAGR versus ICLR at 20.93%.
- Is BBIO or ICLR more profitable?
- ICLR runs the higher net margin — BBIO at -97.64% versus ICLR at 3.99%.
- How have BBIO and ICLR total returns compared?
- Over the past 5 years, BBIO delivered 7.38% and ICLR delivered -8.50% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ICON Public P/E ratioBridgeBio Pharma ROEICON Public ROEBridgeBio Pharma operating marginICON Public operating marginBridgeBio Pharma revenue growthICON Public revenue growthBridgeBio Pharma free cash flowICON Public free cash flow
BridgeBio Pharma & ICON Public appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.